Literature DB >> 24014582

Progressive external ophthalmoplegia (PEO) due to a mutation in the C10orf2 (PEO1) gene mimicking a myasthenic crisis.

Dolores Gonzalez-Moron1, Jose Bueri, Marcelo Andres Kauffman.   

Abstract

We described a case of a patient with autosomal dominant progressive external ophthalmoplegia (PEO) who presented with the acute onset dysphagia, quadriparesis, ptosis and respiratory insufficiency following a cardiac procedure and mimicking a myasthenic crisis. A pathogenic mutation in the C10orf2 (PEO1) gene was confirmed. The unusual presentation of our patient contributes to expand the clinical phenotype of PEO1 mutations and reinforces the need to consider mitochondrial myopathy as differential diagnosis of myasthenia gravis even in the case of acute onset symptoms.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24014582      PMCID: PMC3794138          DOI: 10.1136/bcr-2013-010181

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  11 in total

1.  Diagnosis of mitochondrial disorders applying massive pyrosequencing.

Authors:  Marcelo Andrés Kauffman; Dolores Gonzlez-Morón; Damián Consalvo; Gastón Westergaard; Martín Vazquez; Estefanía Mancini; Ana Lía Taratuto; Raúl Rey; Silvia Kochen
Journal:  Mol Biol Rep       Date:  2012-06       Impact factor: 2.316

2.  CPEO and KSS differ in the percentage and location of the mtDNA deletion.

Authors:  Ester López-Gallardo; Manuel J López-Pérez; Julio Montoya; Eduardo Ruiz-Pesini
Journal:  Mitochondrion       Date:  2009-05-04       Impact factor: 4.160

3.  Novel Twinkle gene mutation in autosomal dominant progressive external ophthalmoplegia and multisystem failure.

Authors:  S Bohlega; G Van Goethem; A Al Semari; A Löfgren; M Al Hamed; C Van Broeckhoven; M Kambouris
Journal:  Neuromuscul Disord       Date:  2009-10-22       Impact factor: 4.296

Review 4.  Drugs interfering with mitochondrial disorders.

Authors:  Josef Finsterer; Liane Segall
Journal:  Drug Chem Toxicol       Date:  2010-04       Impact factor: 3.356

Review 5.  Update on chronic progressive external ophthalmoplegia.

Authors:  Viktoria Bau; Stephan Zierz
Journal:  Strabismus       Date:  2005-09

6.  Assessment of visual function in chronic progressive external ophthalmoplegia.

Authors:  C Y Yu Wai Man; T Smith; P F Chinnery; D M Turnbull; P G Griffiths
Journal:  Eye (Lond)       Date:  2006-05       Impact factor: 3.775

Review 7.  TWINKLE gene mutation: report of a French family with an autosomal dominant progressive external ophthalmoplegia and literature review.

Authors:  M-L Martin-Negrier; G Sole; C Jardel; C Vital; X Ferrer; A Vital
Journal:  Eur J Neurol       Date:  2010-09-29       Impact factor: 6.089

8.  Clinical and genetic heterogeneity in progressive external ophthalmoplegia due to mutations in polymerase gamma.

Authors:  Massimiliano Filosto; Michelangelo Mancuso; Yutaka Nishigaki; Jacklyn Pancrudo; Yadollah Harati; Clifton Gooch; Ami Mankodi; Lydia Bayne; Eduardo Bonilla; Sara Shanske; Michio Hirano; Salvatore DiMauro
Journal:  Arch Neurol       Date:  2003-09

Review 9.  Myasthenia gravis: diagnostic mimics.

Authors:  John W Engstrom
Journal:  Semin Neurol       Date:  2004-06       Impact factor: 3.420

10.  Novel Twinkle (PEO1) gene mutations in mendelian progressive external ophthalmoplegia.

Authors:  Roberta Virgilio; Dario Ronchi; Georgios M Hadjigeorgiou; Andreina Bordoni; Francesca Saladino; Maurizio Moggio; Laura Adobbati; Demetra Kafetsouli; Evangelia Tsironi; Stefano Previtali; Alexandros Papadimitriou; Nereo Bresolin; Giacomo P Comi
Journal:  J Neurol       Date:  2008-06-30       Impact factor: 4.849

View more
  2 in total

Review 1.  Progressive External Ophthalmoplegia.

Authors:  Collin McClelland; Georgios Manousakis; Michael S Lee
Journal:  Curr Neurol Neurosci Rep       Date:  2016-06       Impact factor: 5.081

Review 2.  Gastrointestinal manifestations of mitochondrial disorders: a systematic review.

Authors:  Josef Finsterer; Marlies Frank
Journal:  Therap Adv Gastroenterol       Date:  2016-10-06       Impact factor: 4.409

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.